( 您好!臺灣時間:2022/05/20 06:52
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::


研究生(外文):sung jing yung
論文名稱(外文):Proteomic analysis of drug-induced apoptosis in Caco-2 cancer cell line by Monascus-productive monacolin K with butyrate
中文關鍵詞:monacolin Kbutyrate二維電泳
外文關鍵詞:monacolin KbutyrateTwo-dimentional electrophoresis
  • 被引用被引用:0
  • 點閱點閱:201
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
Monacolin K屬於statin類藥物為HMG-CoA 還原酶抑制子,藉由抑制HMG-CoA 還原酶活性進而抑制HMG-CoA合成膽固醇,普遍作為膽固醇的調控藥物。相關研究指出statin 有抑制腫瘤細胞活性的作用,推論statin會抑制腫瘤細胞進入增生週期,活化腫瘤抑制蛋白的活性。butyrate為腸道微生物的發酵產物,和statin有協同抑制腫瘤細胞活性誘導細胞凋亡。在本研究中利用蛋白質體分析系統分析monacolin K和butyrate處理Caco-2腫瘤細胞誘導腫瘤細胞活性和誘導細胞凋亡的趨勢,顯微鏡觀察分析monacolin K和butyrate處理腫瘤細胞對腫瘤細胞的形態變化,二維蛋白質膠體電泳分析藥物處理對腫瘤細胞的蛋白質表現的變化。研究中獲得20個可能和monacolin K誘導細胞凋亡的相關蛋白質,為cytokeratin家族、Peroxiredoxin家族、GSTP1-1等。cytokeratin家族和GSTP1-1在相關研究已證實和腫瘤活性的表現有關,以西方墨點法分析,cytokeratin 家族和GSTP1-1確實受monacolin K和butyrate的調控,monacolin K和butyrate對腫瘤細胞蛋白質表現具有偕同抑制。
Monacolin K for statin family of medicine is inhibitor for HMG-CoA reductase. Monacolin K limit cholesterol synthesis by suppressing HMG-CoA reductase Activation, is generally regard as the regulation and control medicine of the cholesterol. There is function which suppress tumour cell's activation on relevant research point out statin, inference statin will suppress the tumour cell to start cell hyperplasia cycle, and activates the activation that the tumour suppresses the albumen. Butyrate is a fermented product of the intestinal microorganism, and statin suppresses tumour cell's activation to lead cells to wither to die in coordination. Utilize proteomic analysis monacolin K and butyrate induce Caco-2 tumour cell death and apoptotic. The microscope observes analyses monacolin K and butyrate deal induce tumour cell's shape change. Two-dimentional protein colloid electrophoresis analyse medicine deal induce protein expression change in tumour cell. We get 20 relevant proteins that may lead cells to wither and die with monacolin K while studying, it is cytokeratin family, Peroxiredoxin family, and GSTP1-1. Cytokeratin family and GSTP1-1 have already in relevant research verified that has been involved in behavior of the tumour activation, west blot analysis expression, cytokeratin family and GSTP1-1 really receive the regulation and control of monacolin K and butyrate, there are monacolin K and butyrate together with suppressing to that the tumour cell protein behave.

1. Olson M. F., and Marais R.(2000) Ras protein signaling. Seminars in immunology. 12, 63-73.
2. Graaf M. R., Beiderbeck A. B., Egbersts A. C. G., Richel D. J., and Guchelaar H.(2004) The risk of cancer users of statins. J Clin Oncol, 22, 2388-2394.
3. Brown M. S., and Goldstein J. L.(1980) Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinationg isoproenoid synthesis and cell growth. 21, 505-517.
4. Wong W., Dimitroulakos J., Minden M., and Penn L.,(2002) HMG-CoA reductase inhibitiors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia, 16, 508-519.
5. Boudreau D. M., Gardiner J. S., Malone K. E., Heckbert S. R., Blough D. K., and Daling J. R.,(2004) The association between 3-hydroxy-3-methylglutaryl gonenzyme A inhibitor use and breast carcinoma risk among postmenopausal women. Cancer, 100,2308-16.
6. Williamst K. J., Brocia R. W., and Fisher E. A.,(1990) The unstirred water layer as a site of control of apolipoprotein B secretion.
The Joural of Biological Chemistry, 258(28), 16741-16744.
7. Golderg I. J., Holleran S. Ramakrishnan R., Adams M., Palmer R. H., Dell R. B., and Goodman D. S.,(1990) Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism. J. Clin. Invest., 86, 801-808.
8. Freeman M. L., Prigge W. F., Hunninghake D. B., Duane W. C., and Gebhard R. L.,(1988) Intestinal HMG-CoA reductase activity is low in hypercholerterolemic patients and is further decreased with lovastatin therapy. J. Lipid res., 29, 839-845.
9. Edwards P. A., Lan S., and Fogelman A. M.,(1984) High density lipoproteins and lecithin increase the activity of 3-hydroxy-3- methyllglutaryl coenzyme A reductase by increasing the rate of synthesis and decreasing the rate of degradation of the enzyme. Issue of July, 10, 8190-8194.
10. Vishnuvardhan D., and Beinfeld M. C.,(2000) Lovastatin is a potent inhibitor of cholecystokinin secretion in endocrine tumor cells in culture. Peptides, 21, 553-557.
11. Robison R. L., Suter W., and Cox R. H.,(1994) Carcinogenicity and mutagenicity studies with fluvastatin, a new entir synthetic HMG-CoA reductase inhibitor. Fundamental and Applied Toxicology, 23, 9-20.
12. Strandberg T. E., Pyörälä K., Cook T. J., Wilhelmsen L., Faergerman O., Thorgeirsson G., Pedersern T. R., Kjekshus J., for the 45 groups.(2004) Mortality and incidence of cancer during 10-years follow-up of the Scandinavian simvastatin survival study(4S). Lancet, 364, 771-777.
13. Mayer R. J., Adams J. L., Bossard M. J., and Berkhout T. A.,(1991) Effects of a novel loanostaerol 14α-demethylase inhibitor on the regulation of 3-hydroxy-3-methylglutary-coenzyme A reductase in Hep G2 cells. Issue of October, 25, 20070-20078.
14. Lorenz R. T., and Parks L. W.,(1990) Effects of lovastatin(mevinolin) on sterol levels and on activity of azoles in saccharomyces cerevisiae. Antimicroial Agents and Chemotherapy, 34(9), 1660-1665.
15. Hrboticky N., Tang L., Zimmer B., Lux, I., and Weber P. C.,(1994) Lovastatin increases arachidonic acid levels and stimulates thromboxane synthesis in human liver and monocytic cell lines. J. Clin. Invest, 93, 195-203.
16. Singer I. I., Scott S., Kazazis D. M., and Huff J. W.,(1988) Lovastatin, an inhibitor of cholesterol synthesis, induces hydroxymethylglutaryl-coenzyme A reductase directly on membranes of expanded smooth endoplasmic reticulum in rat hepatocytes. Proc. Natl. Acad. Sci. USA, 85, 5264-5268.
17. Bergstrom J. D., wong G. A., Edwards P. A., and Edmond J.,(1984) The regulation of acetoacetyl-CoA synthetase activity by modulators of cholesterol synthesis in vivo and the utilization of acetoacetate for cholesterogenesis. J. Biological Chemistry, 23, 14548-14553.
18. Bellini M. J., Polo M. P., Alaniz M. J. T., Bravo M. G..,(2003) Effect of simvastatin on the uptake and metabolic conversion of palmitic, dihomo-ν-linoleic and α-linolenic acids in A549 cells. Prostaglandins, Leukotrienes and Essential Fatty Acids, 69, 351-357.
19. MO H., and Elson C. E.,(2004) Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol, 229, 567-585.
20. Petras S. F., Lindsey S., and Harwood H. J., Jr.(1999) HMG-CoA reductase regulation: use of structurally diverse first half-reaction squalene synthetase inhibitors to characterize the site of mevalonate-derived nonsterol regulator production in cultured IM-9 cells. J. Lipid res., 40, 24-38.
21. Thunyakitpisal P. D., and Chaisuparat R.,(2004) Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9(gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J. Pharmacol Sci., 94, 403-409.
22. Bansal N., Houle A., and Melnykovych G.,(1991) Apoptosis: mode of cell death induced in T cell leukemia lines by dexamethasone and other agents. Faseb J., 5, 211-216.
23. Osadchy A., Drucker L., Radnay J., Shapira H., and Lishner M.,(2004) Microenvironment factors do not afford myeloma cell lines protection from simvastatin. Eur J. Haemarol, 73, 183-190.
24. Pérez-Sala D., and Mollinedo, F.,(1994) Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochemical and Biophysical Rsearch Communications, 199(3), 1209-1215.
25. Jones K. D., Couldwell W. T., Hinton D. R., Su Y., He S., Anker L., and Law R. E.,(1994) Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochemical and Biophysical Research Communications, 205(3), 1681-1687.
26. Dimitroulakos J., Ye L. Y., Benzaquen M., Moore M. J., Yeger H., and Penn L. Z.,(2001) Differential sensitively of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clinical Cancer Research, 7, 158-167.
27. Mattingly R. R., Gibbs R. A., Menard R. E., and Reiners JR J. J., (2002) Potent suppression of proliferation of A10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allyfarnesol, an inhibitor of protein farnesyltransferase. J. Pharmacology and experimental therapeutics, 303, 74-81.
28. Katano H., Pesnicak L., and Cohen J. I.,(2004) Simvastatin induces apoptosis of Epstein-Barr virus(EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. PNAS, 101, 4960-4965.
29. Agarwal B., Bhendwal S., Halmos B., Moss S. F., Ramey W. G., Holt P. R.,(1999) Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clinical Cancer Research, 5, 2223-2229.
30. Otsuki Y.,(2004) Tissue specificity of apoptotic signal transduction. The Clinical Electon Microscopy Society of Japan, 37, 163-169.
31. Denoyelle C., Albanese P., Uzan G., Hong L., Vannier J., Soria J., Soria C.,(2002) Molecular mechanism of the anti-cancer activity of cerivstatin an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cellular Signalling, 15, 327-338.
32. Wang CY., Zhong WB., Chang TC., Lai SM., and Tsai YF.,(2003) Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab, 88, 3021-3026.
33. Vamvakopoulos J. E., and Green C.,(2003) HMG-CoA reductase inhibitor aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statin-mediated vasculoprotection. BMC Cardiovascular Disorders, 1-10.
34. Zhong WB., Wang CY., Chang TC., and Lee WS.,(2003) Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranyleranylation and de nove protein synthesis. Endocrinology, 144, 3852-3859.
35. Mitchell D. I., and Cowan A. K.,(2003) Mevastatin-induced inhibition of cell growth in avocado suspension cultures and reversal by isoprenoid compounds. African Journal of Biotechnology, 2(9), 264-270.
36. Srikant C. B.,(1995) Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituitary cells. Biochemical and Biophysical Research Communications, 209(2), 400-406.
37. Guijarro C., Blanco-Colio L. M., Ortego M., Alonso C., Ortiz A., Plaza J. J., Díaz C., Hernández G., Egido J.,(1998) 3-hydroxy-3- methylglutaryl coenzyme A reducatase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res., 83, 490-500.
38. Feleszko W., Mlynarczuk I., Olszewska D., Jalili A., Grzela T., Lasek W.,(2002) Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma VIA an apoptosis-dependent mechanism. Int. J. Cancer, 100, 111-118.
39. Denoyelle C., Vasse M., Körner M., Mishal Z., Ganné F., Vannier JP., Soria J., and Soria C.,(2001) Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis, 22(8), 1139-1148.
40. Agarwal B., Halmos B., Feoktistov A. S., Protiva P., Ramey W. G., Chen M., Pothoulakis C., Lamont J. T., and Holt P. R.,(2002) Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis, 23(3), 521-528.
41. Chen Z., Moyana T., Saxena A., Warrington R., Jia Z., and Xiang J.,(2001) Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apopotic/necrotic tumor cells. Int. J. Cancer, 93, 539-548.
42. Schmidt F., Groscurth P., Kermer M., Dichgans J., and Weller M.,(2001) Lovastatin and phenylacetate induce apoptosis but not differentiation, in human malignant glioma cells. Acta Neuropathol, 101, 217-224.
43. Shibata MA., Ito Y., Morimoto J., and Otsuki Y.,(2004) Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptosis mechanism. Carcinogenesis, 25(10), 1887-1898.
44. Freeman M. L., Prigge W. F., Hunninghake D. B., Duane W. C., and Gebhard R. L.,(1988) Intestinal HMG-CoA reductase activity is low in hyperchoerterolemic patients and is further decreased with lovastatin therapy. J. Lipid Res., 29, 839-845.
45. Huff M. W., Telford D. E., Woodcroft K. and Strong W. L. P.,(1985) Mevinolin and cholertyramine inhibit the direct synthesis of low density lipoprotein apolipoprotein synthesis of low density lipoprotein apolipoprotein B in minature pigs. J. Lipid Res., 26, 1175-1186.
46. Feleszko W., Mlynarczuk I., Balkowiec-Iskra E. Z., Czajka A., Šwitaj T., Stoklosa T., Giermasz A., and Jakóbisiak M.,(2000) Lovastatin potentiate antitumor activity and attenuates cardiotoxicity of doxorubicin in there tumor model in mice. Clinical Cancer Research, 6, 2044-2052.
47. van de Donk NWCJ., Kamphuis MMJ., Lokhorst HM., and Bloem AC.,(2002) The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia, 16, 1362-1371.
48. Rubins J. B., Greatens T., Kratzke R. A., Tan A. T., Polunovsky V. A., and Bitterman P.,(1998) Lovastatin induces apoptosis in malignant mesothelioma cells. Am. J. Respir Crit Care Med., 157, 1616-1622.
49. Larner J., Jane J., Laws E., Packer R., Myer C., and Shaffrey M.,(1998) A phase Ⅰ-Ⅱ trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am. J. Clin. Oncol, 21, 579-583.
50. Maltese W. A., Defendlni R., Green R. A., Sheriden K. M., and Donley D. K.,(1985) Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3- methylglutaryl-coenzyme A reductase. J. Clin. Invest, 76, 1748-1754.
51. Rao s., Porter D. C., Chen X., Herliczek T., Lowe M., and Keyomarst K.,(1999) Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc. Natl. Acad. Sci. USA, 96, 77979-7802.
52. Wang W. and Macaulay R. J. B.,(1999) Apoptosis of medulloblastoma cells in vitro follows inhibition of farnesylation using manumycin A. J.Cancer., 82, 430-434.
53. Maltese W. A., Sheridan K. M., Repko, E. M. and Erdman R. A.(1990) Post- translational modification of low molecular mass GTP-binding proteins by isoprenoid. The Journal of Biological Chemistry, 2148-2155.
54. Jackson J. H., Cochrane C. G., Bourne J. R., Solski P. A., Buss J. E., and Der C.,(1990) Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. USA, 87, 3042-3046.
55. Rambaratsingh R. A., Stone J. C., Blumberg P. M., and Lorenzo P. S., (2003) RasGRP1 represents a novel non-protein kinase C phorbol ester signaling pathway in mouse epidermal keratinocytes. The Journal of Biological Chemistry, 278(52), 52792-52801.
56. Calvent R. J., Tepper S., Diwan B. A., Anderson L. M., and Kritchevsky D.,(2003) Treatment with lovastatin, cholestyramine or niacin alters K-ras membrane association in mouse lung in a strain-dependent manner: results in females. Biochemical Pharmacology, 66, 393-403.
57. Bouterfa H. L., Sattelmeyer V., Czub S., Vordermark D., Boosen K., and Tonn J. C.,(2000) Inhibition of ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human clioblastoma cells. Anticancer Research, 20, 2761-2772.
58. Cesen-Cummings K., Waring K. A., and Ruch R. J.,(1998) Role of protein kinase C in the deficient gap junctional intercellular communication of K-ras-transformed murine lung epithelial cells. Anticancer Research, 18, 4343-4346.
59. Skaletz-Rorowsk A., Müller J. G., Kroke A., Walernberger J., Pulawski E., Pinkernell K., Breithardt G.,(2001) Lovastatin blocks basic fibroblast growth factor-induced mitogen-activated protein kinase signaling in coronary smooth muscle cells via phosphatase inhibition. European Jourmal of Cell Biology, 80, 207-212.
60. Calvent R. J., Ramakrishna G., Tepper S., Diwan B. A., Anderson L. M., and Kritchevsky D.,(2002) Alterations in membrane-bound and cytoplasmic K-ras protein levels in mouse lung induced by treatment with lovastatin, cholestyramine, or niacin: effects are highly mouse strain dependent. Biochemical Pharmacology, 64, 41-48.
61. Hancock J. F., Magee A. I., Childs J. E., and Marshall C. J.,(1989) All ras protein are polyisoprenylated but only some are palmitoylated. Cell, 57, 1167-1177.
62. Bassa B. V., Roh D. D., Vaziri N. D., Kirschenbaum M. A., Kamanna V. S.,(1999) Effect of inhibition of cholesterol synthesis pathway on the activation of ras and MAP kinase in mesangial cells. Biochimica et Biophysica Acta, 1449, 137-149.
63. Chang F., Steelamn L. S., Shelton J. G., Lee J. T., Navolanic P. M., Blalock W. L., Franklin R., and McCubrey J. A.,(2003) Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway(review). International Journal of Oncology, 22, 469-480.
64. Wu J., Wong W. WL., Khosravi F., Minden M. D., and Penn L. Z.,(2004) Bocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Research, 64, 6461-6468.
65. Nübel T., Dippold W., Kleinert H., Kaina B., and Fritz G.,(2004) Lovastatin inhibits Rho-regulated expression of E-selectin by TNFα and attenuates tumor cell adhesion. The FASEB Joural, 18, 140-142.
66. Kim JS., Pirnia F., Cho Y. H., Nguyen PM., Knepper B., Tsokos M., Schulte T. W. Birrer M. J., Blagosklonny M. V., Schaefer O., Mushinski J. F., and Trepel J. B.,(2000) Lovastatin induces apotosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint. Oncogene, 19, 6082-6090.
67. Park C., Lee I. and Kang W. K.,(2001) Lovastatin-induced E2F-1 modulation and its effect on protate cancer cell death. Carcinogenesis, 22(10), 1727-1731.
68. Ukomadu C., and Dutta A.,(2003) Inhibition of cdk2 activating phosphorylation by mevastatin. The Journal of Biological Chemistry, 278(7), 4840-4846.
69. Barrentt K. L. B., Demiranda D., and Katula K. S.,(2002) Cyclin bi promoter activity and function cdk1 complex formation in G1 phase of human breast cancer cells. Cell Biology International, 26(1), 19-28.
70. Germano D., Pacilio C., Cancemi M., Cancemi M., Cicatiello L., Altucci L., Petrizzia V. B., Sperandio C., Salzano S., Michalides R. J. A. M., Taya Y., Bresciani F., and Weisz A.,(2001) Inhibition of human breast cancer cell growth by blockade of the mevalonate-protein prenylation pathway is not prevented by overexpression of cyclin D1. Breast Cancer Research and Treatment, 67, 23-33.
71. Holstein S. A., and Hohl R. J.,(2001) Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Molecular Cancer Therapeutics, 1, 141-149.
72. Schmidmaier R., Baumann P., Simsek M., Dayyani F., Emmerich B., and Meinhard G.,(2004) The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion- mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood, 104, 1825-1832.
73. Dmoszyñska A., Podhorecka M., Roliñski J., Soroka- Woktaszko M.,(2004) Influence of lovastatin on Bcl-2 and Bax expression by plasma cells and T lymphocytes in short-term cultures of multiple myeloma bone marrow mononuclear cells. Polish Journal of Pharmacology, 56, 485-489.
74. Sinensky M., and Logel J.,(1983) Inhibition of degradation of 3-hydroxy-3-methylglutaryl conenzyme A reductase by mevinolin. The Journal of Biological Chemistry, 25, 8547-8549.
75. Wang QF., Chen JC., Hsieh SJ., Cheng CC., Hsu SL.,(2001) Regulation of Bcl-2 family molecules and activation of caspase cascade involved in gypensides-induced apoptosis in human hepatoma cells. Cancer Letters, 18, 169-178.
76. Ukomadu C., and Dutta A.,(2003) Inhibition of cdk2 activating phosphorylation by mevastatin. The Journal of Biological Chemstry, 278(9),4840-4846.
77. Shilbata MA., Kavanaugh C., Shibata E., Abe H., Nguyen PM., Otsuki Y., Trepel J. B., and Green J. E.,(2003) Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis, 24(3), 453-459.
78. Shilbata MA., Ito Y., Morimoto J., and Otsuki Y.,(2004) Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptosis mechanism. Carcinogenesis, 25, 1887-1898.
79. Lee S. J., Ha M. J., Lee J., Nguyen PM., Choi Y. H., Pirnia F., Kang WK., Wang XF., Kim SJ., and T J. B.,(1998) Inhibation of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of P21WAF1/CIP1 in human prostase carcinoma cells. The Journal of Biological Chemstry, 24, 10618-10623.
80. Rao S., Gray-Bablin J., Herliczek T. W., and Keyomarsi K.,(1999) The biphasic induction of p21 and p27 in breast cancer cells by modulators of cAMP is posttranscriptionally regulated and independent of the PKA pathway. Experimental Cell Research, 252, 211-223.
81. Ukomadu C., and Dutta A.,(2003) P21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. The Journal of Biological Chemistry, 287(44), 43586-43594.
82. Rao S., Portex D. C., Chen X., Herliczek T., Lowe M., and Keyomarsi K.,(1999) Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc. Natl. Acad. Sci. USA, 96, 7797-7802.
83. Lanfs U., Marra D., Node K., and Liao J. K.,(1999) 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing Rho GTPase-induced Down-regulation of p27kip1. The Journal of Biological Chemistry, 274(31), 21926-21931.
84. Vidal A., Millard S. S., Miller J. P., and Koff A.,(2002) Rho activity can alter the translation of p27 mRNA and is important for rasv12-induced transformation in a manner dependent on p27 status. The Journal of Biological Chemistry, 277(19), 16433-16440.
85. Danesh F. R., Sadegh M. M., Amro N., Phillips C., Zeng L., Sahai A., and Kanwar Y. S.,(2002) 3-hydroxy-3-methylgluataryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cell via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. PNAS, 99(12), 8301-8305.
86. Indolfi C., Lorenzo E. D., Perrino C., Stingone A. M., Cucio A., Torella D., Cittadini A., Cardone L., Coppola C., Cavuto L., Arcucci O., Sacca L., Avvedimento E. V., Chiariello M.,(2002) Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Cirulation, 106, 2118-2124,
87. Puga A., Haychaudhuri B., and Nebert D.,(1992) Transcriptional derpression of the murine Cyp1a-1 gene by meviolin. FASEB J., 6, 777-785.
88. Verma J. N., and Goldfine H.,(1985) Phosphatidylserine decarboxylase from Clostridium butyricum. J. lipid Res., 26, 610-616.
89. Hinnebusch B. F., Meng S., Wu J. T., Archer S. Y., and Hodin R. A.,(2002) The effect of short-chain fatty acid on human colon caner cell phenotype are associated with histone hyperacetylation. J. Nutr., 132, 1012-1017.
90. Lévy P., Robin H., Bertrand F., Kornprobst M., and Capeau J.,(2003) Butyrate-treated colonic Caco-2 cells exhipbit defective integrin-mediated signaling together with increased apoptosis and differentiation. J. Cell. Physiol., 197, 336-347.
91. Emenaker N. J., Calaf G. M. Cox D. Basson M. D., and Qureshi N.,(2001) Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in vitro cell culture model. J. Nutr., 131, 3041s-3046s.
92. Lupton J. R.,(2004) Microbial degradation products influence colon risk: the butyrate controversy. J. Nutr., 134, 479-482.
93. Marcil V., Delvin E., Garofalo C., and Levy E.,(2003) Butyrate impairs lipid transport by inhiting microsomal triglyceride transfer protein in Caco-2 cells. J. Nutr., 133, 2180-2183.
94. Kuefer R., Hofer MD., Altung V., Zorn C., Genze F., Kunzi-Rapp K., Hautmann RE., and Gschwend JE.,(2004) Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. British Joumal of Cancer, 90, 535-541.
95. Wächtershäuser A., and Stein J.,(2001) Butyrate-induced differentiation of Caco-2 cells occurs independently from p27. Biochemical and Biophysical Research Communications, 281, 295-299.
96. Wächtershäuser A., Akoglu B., and Stein J.,(2001) HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis, 22, 1061-1067.
97. Seow T. K., Ong SE., Liang R. C. M., Ren EC., Chan L., Ou K., Chung M. C. M.,(2000) Two-dimesional electrophoresis map of the human hepatocellular carcinoma cell line, HCC-M, and identification of the separated protein by mass spectrometry. Electrophoresis, 21, 1787-1813.
98. Mann M., Hendrickson R. C., and Pandey A.,(2001) Analysis of proteins and proteomes by mass spectrometry. Annu. Rev. Biochem., 70, 434-73.
99. Grinyer J., Mckay M., Nevalainen H., Herbert B. R., (2004) Fungal proteomics: initial mapping of biological control strain Trichoderma harzianum. Curr Genet, 45, 163-169
100.Regauer S., Franke W. W., and Virtanen I.,(1985) Interrmediate filament cytoskeleton of amnion epithelium and cultured amnion epithelial cells: expression of epidermal cytokeratins in cells of simple epithelium. The Journal of Cell Biology, 100, 997-1009.
101.Bosch F. X., Leube R. E., Achtstätter T., Moll R., and Franke W.,(1988) Expression of simple epithelial type cytokeratins in stratinfied epithelia as detected by immunolocalization and Hybridization in situ. The Journal of Cell Biology, 106, 1635-1648.
102.Baricault L., Néchaud B., Sapin C., Codogno P., Denoule P., and Trugnan G.,(1994) The network organization and the phosphorylation of cytokeratins are concomitantly modified by forskorlin in the enterocyte-like differentiated Caco-2 cell line. J. Cell Sci., 107, 2909-2918.
103.Yuan C.-C., Huang H.-C., Tsai L.-C., Ng H.-T. and Huang T.-S., (1997) Cytokeratin-19 associated with apoptosis and chemosensitivity in human cervical cancer cells. Apoptosis, 2, 101-105.
104.Kamiya M., Ichiki Y., Kamiya H, Yamamoto A., and Kitajima Y.,(2003) Detection of nonmelanorma skin cancer micrometastases in lymph nodes by using reverse transcriptase-polymerase chain reaction for keratin 19 mRNA. British Journal of Dermatology, 149, 998-1005.
105.Pires F. R., Chen S.-Y., Perez D. E. da C., Almeida O. P., Kowalski L. P.,(2004) Cytokeratin expression in central mucoepidermoid carcinoma and glandular odontogenic cyst. Oral Oncology, 40, 545-551.
106. Yuan C.-C., Huang H.-C., Tsai L.-C., Ng H.-T. and Huang T.-S.,(1998) Elevated cytokeratin-19 expression associated with apoptotic resistance and malignant progression of human cervical carcinoma. Apoptosis, 3, 161-169.
107.Pei R.-J., Danbara N., Kyutoku M. T., Yuri T., and Tsubura A.,(2004) Immunohistochemical protein of Mallory body by a panel of anti-cytokeratin antibodies. Med Electron Microsc, 37, 114-118.
108.Morrow C. S., Smitherman P. K., and Townsend A. J.,(2000) Role of multidrug-reistance protein2 in gutathione S-transferase P1-1-mediated resistance to 4-nitroquinoline 1-oxide toxicities in HepG2 cells. Molecular carcinogenesis, 29, 170-178.
109.Berendsen C. L., Peters W. H. M., Scheffer P. G.., Bouman A. A., Boven E., and Newling D. W. W.,(1997) Glutathione S-transferase activity and subunit composition in transitional cell cancer and mucosa of the human bladder. Urology, 49, 644-651.
110.Bruin W. C. C., Wagenmans M. J. M., and Peters W. H. M.,(2000) Expression of glutathione S-transferase α, P1-1 and T1-1 in the hnamn gastrointestinal tract. Jpn. J. Cancer. Res., 91, 310-316.
111.Morecau F., Duvoix A., Delhalle S., Schnekenburger M., Dicato M., and Diederich M.,(2004) Regulation of glutathione S-transferase P1-1 gene expression by NF-kappaB in tumor necorsis factor alpha-treated K562 leukemia cells. Biochemical Pharmacology, 67, 1227-1238.
112.Duvoix A., Morceau F., Delhalle S., Schmitz M., Schnekenburger M., Galteau M.-M., Dicato M., and Diederich M.,(2003) Induction of apoptosis by curcumin: mediation by glutathione S-transferase P1-1 inhibition. Biochemical Pharmacology, 66, 1475-1483.
目 錄
前 言...........................1
六、 Statin和腫瘤細胞活性抑制和雕亡誘導的相關研究....6
七、 monacolin K的相關研究...............7
八、butyrae 和腫瘤相關性研究...............8
一、一維蛋白質膠體電泳樣品前處理............ 15
七、膠體內蛋白質分解(In-gel digestion for SYPRO ruby stain).19
九、SDS PAGE細胞蛋白質樣品製備............20
SDS PAGE 蛋白質膠體電泳................20
一、SDS PAGE細胞蛋白質樣品製備............20
二、SDS PAGE 蛋白質濃度定量..............20
三、SDS PAGE蛋白質膠體電泳..............21
1. Monacolin K單一處理................28
2.Monacolin K 和butyrate 共同處理...........29討論...........................31
註: 此連結為研究生畢業學校所提供,不一定有電子全文可供下載,若連結有誤,請點選上方之〝勘誤回報〞功能,我們會盡快修正,謝謝!
第一頁 上一頁 下一頁 最後一頁 top